Most Active Stock: GTx, Inc. (NASDAQ:GTXI)


Baird Downgrades GTx, Inc. (NASDAQ:GTXI)’s stock to Neutral with no specific Price Target. This rating was issued on 9/21/18. The stock recently closed its previous session at $1.5 by showing a percentage change of -3.85% from its previous day closing price of $1.56.

Price Target is basically a projection of future price of a company’s stock by the expert analysis of investment analysts or investment firms. There may be various price targets for a stock. These analysts and investment firms use various valuation methods to decide a price target for a stock.

Several investment firms issued their expert ratings on GTx, Inc. (NASDAQ:GTXI) in which Baird Initiates Coverage On GTx, Inc. (NASDAQ:GTXI) to Outperform by settling a price target of $17 on 11/21/17. Stifel Nicolaus Initiates Coverage On the stock to Buy on 11/09/17 by stationing a price target of $16. Jefferies Maintains the company’s stock to Hold on 8/10/16 by setting a price target of $0.5. Lazard Downgrades GTx, Inc. (NASDAQ:GTXI) to Neutral with no specific Price Target.

GTx, Inc. (NASDAQ:GTXI) currently has a consensus Price Target of $2. While some analysts have a High Price target for the stock of $2 and a Low Price Target of $2.

Several sell side analysts reviewed their recommendations on GTx, Inc. (NASDAQ:GTXI) where 0 analyst have rated the stock as Strong Buy, 0 analysts said it’s a Buy, 2 rated the stock as Hold, 0 analysts reported Underperform and 0 analysts gave their recommendations as Sell. (Current Month Yahoo Finance Ratings)

Zacks Investment Research also rated the stock with a value of 3. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, GTx, Inc. (NASDAQ:GTXI) reported its Actual EPS of $-0.43/share. The analysts offering Earnings Estimates for the company were believing that GTx, Inc. (NASDAQ:GTXI) could bring EPS of $-0.43/share. The difference between Actual EPS and Estimated EPS was 0 Percent. Thus the company showed an Earnings Surprise of 0 Percent.

GTx, Inc. (NASDAQ:GTXI) has a market capitalization of 36.07 Million. The stock traded with the volume of 1.5 Million shares in the last trading session. The stock touched its high share price of $25.60 on 09/13/18 and the stock also touched its Lowest price in the last 52-weeks of trading on 10/03/18 as $1.32. The company has a 1 Year high price target of $2. The stock is currently trading with a distance of 20-Day Simple Moving Average (SMA20) of -81.46%. The Moving Average SMA50 is -90.07% while SMA200 is -90.83%.

GTx, Inc. (NASDAQ:GTXI) is currently showing its ROA (Return on Assets) of -89.8%. The Return on Investment (ROI) is at 0% while it’s Return on Equity (ROE) value stands at -110.7%. The stock currently shows its YTD (Year to Date) performance of -88.2 percent while its Weekly performance value is 6.38%. The Monthly and Yearly performances are -93.91 percent and -82.31 percent respectively. The Relative Volume value measured for GTx, Inc. (NASDAQ:GTXI) is 0.82. The Average Volume (3 months) is 1.84 Million.

The stock currently has its Annual Dividend of $0 and an annual Dividend Yield of 0 Percent. GTXI has P/E (Price to Earnings ttm) value of 0, Forward P/E of 0, P/C (Price to cash per share) of 0.58 and Price to Free Cash Flow (P/FCF) value of 0. The stock is showing its Operating Margin of 0 percent.

Company Profile:

GTx, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other serious medical conditions. GTx’s lead candidate is enobosarm, a selective androgen receptor modulator, or SARM, targeted at the androgen receptor, or AR, in women with advanced breast cancer whose tumors express the androgen receptor and the estrogen receptor, or ER, and women with AR positive triple negative breast cancer. GTx is also evaluating enobosarm for the treatment of other serious medical conditions where building lean body mass is important.